PMID- 30057316
OWN - NLM
STAT- MEDLINE
DCOM- 20190312
LR  - 20190312
IS  - 1090-2104 (Electronic)
IS  - 0006-291X (Linking)
VI  - 503
IP  - 3
DP  - 2018 Sep 10
TI  - Pioglitazone induces hypoxia-inducible factor 1 activation in human renal 
      proximal tubular epithelial cell line HK-2.
PG  - 1682-1688
LID - S0006-291X(18)31601-2 [pii]
LID - 10.1016/j.bbrc.2018.07.099 [doi]
AB  - We previously reported that fatty acid-bearing albumin but not fatty 
      acid-depleted albumin induces hypoxia-inducible factor-1 (HIF-1) activation in 
      human renal proximal tubular epithelial cell line HK-2. Then, an increase in mRNA 
      expression of peroxisome proliferator-activated receptor gamma (PPARgamma) was 
      observed on treatment with fatty acid-bearing albumin but not fatty acid-depleted 
      albumin. The aim of this study was to determine whether a PPARgamma agonist, 
      pioglitazone, induces HIF-1 activation or not. Treatment with pioglitazone 
      induced HIF-1alpha mRNA as well as PPARgamma mRNA expression in a concentration dependent 
      manner. In addition, pioglitazone increased HIF-1 target genes such as the mRNAs 
      of glucose transporter 1 (GLUT1) and breast cancer resistance protein 
      (BCRP/ABCG2), in a concentration-dependent manner. Consistent with the increases 
      in GLUT1 and ABCG2 mRNAs, protein expression of GLUT1 and BCRP was increased by 
      pioglitazone. In addition, GLUT inhibitor phloretin-sensitive D-[(3)H]glucose 
      uptake activity and BCRP inhibitor Ko143-sensitive accumulation of Hoecsht33342, 
      a BCRP substrate, were significantly enhanced by treatment with pioglitazone. 
      These findings suggest that PPARgamma activation by pioglitazone leads to HIF-1 
      protein expression induction followed by changes in HIF-1 target gene expression 
      and protein product activity.
CI  - Copyright (c) 2018 Elsevier Inc. All rights reserved.
FAU - Urakami-Takebayashi, Yumiko
AU  - Urakami-Takebayashi Y
AD  - Department of Pharmaceutics, Osaka University of Pharmaceutical Sciences, 4-20-1 
      Nasahara, Takatsuki, Osaka, 569-1094, Japan.
FAU - Kuroda, Yukimi
AU  - Kuroda Y
AD  - Department of Pharmaceutics, Osaka University of Pharmaceutical Sciences, 4-20-1 
      Nasahara, Takatsuki, Osaka, 569-1094, Japan.
FAU - Murata, Tadashi
AU  - Murata T
AD  - Department of Pharmaceutics, Osaka University of Pharmaceutical Sciences, 4-20-1 
      Nasahara, Takatsuki, Osaka, 569-1094, Japan.
FAU - Miyazaki, Makoto
AU  - Miyazaki M
AD  - Department of Pharmaceutics, Osaka University of Pharmaceutical Sciences, 4-20-1 
      Nasahara, Takatsuki, Osaka, 569-1094, Japan.
FAU - Nagai, Junya
AU  - Nagai J
AD  - Department of Pharmaceutics, Osaka University of Pharmaceutical Sciences, 4-20-1 
      Nasahara, Takatsuki, Osaka, 569-1094, Japan. Electronic address: 
      jnagai@gly.oups.ac.jp.
LA  - eng
PT  - Journal Article
PT  - Research Support, Non-U.S. Gov't
DEP - 20180727
PL  - United States
TA  - Biochem Biophys Res Commun
JT  - Biochemical and biophysical research communications
JID - 0372516
RN  - 0 (Hypoxia-Inducible Factor 1)
RN  - 0 (RNA, Messenger)
RN  - X4OV71U42S (Pioglitazone)
SB  - IM
MH  - Cells, Cultured
MH  - Dose-Response Relationship, Drug
MH  - Epithelial Cells/*drug effects/metabolism
MH  - Humans
MH  - Hypoxia-Inducible Factor 1/genetics/*metabolism
MH  - Pioglitazone/*pharmacology
MH  - RNA, Messenger/genetics/metabolism
MH  - Structure-Activity Relationship
OTO - NOTNLM
OT  - Breast cancer resistance protein
OT  - Facilitative glucose transporter
OT  - Hypoxia-inducible factor-1
OT  - Peroxisome proliferator-activated receptor gamma
OT  - Pioglitazone
OT  - Renal proximal tubular cells
EDAT- 2018/07/31 06:00
MHDA- 2019/03/13 06:00
CRDT- 2018/07/31 06:00
PHST- 2018/07/18 00:00 [received]
PHST- 2018/07/20 00:00 [accepted]
PHST- 2018/07/31 06:00 [pubmed]
PHST- 2019/03/13 06:00 [medline]
PHST- 2018/07/31 06:00 [entrez]
AID - S0006-291X(18)31601-2 [pii]
AID - 10.1016/j.bbrc.2018.07.099 [doi]
PST - ppublish
SO  - Biochem Biophys Res Commun. 2018 Sep 10;503(3):1682-1688. doi: 
      10.1016/j.bbrc.2018.07.099. Epub 2018 Jul 27.